4DMedical shares (ASX: 4DX) saw its remarkable rally take a pause today, with the share price closing 7.07% lower at A$6.31 as technical indicators flashed overbought signs and profit-taking emerged following one of the Australian market’s most explosive runs in recent memory.
4DX opened with a gap to A$7.29 before surrendering the entire gain, closing at the session low in a dramatic intraday reversal that saw prices fall more than 13% from peak to trough. The pullback comes after shares surged 64.75% in the past month and an extraordinary 2,000% over the past year, with the daily Relative Strength Index breaching 72 at the open, a level widely considered overbought by technical analysts.
What Has Been Driving the 4DMedical Rally?
Despite the pullback on the day, 4DMedical remains up substantially from where it traded in late March, with Tuesday’s close representing a test of support at prior consolidation levels rather than a breakdown of the broader uptrend. The company’s market capitalisation has expanded to A$3.72 billion, supported by a string of commercial wins, regulatory approvals, and the upcoming inclusion in the S&P/ASX 200 index effective 20 April 2026.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The inclusion announcement, made by S&P Dow Jones Indices, marks a watershed moment for the Melbourne-based company, which will replace Insignia Financial in Australia’s benchmark index. The move is expected to trigger automatic demand from index-tracking ETFs and expand the company’s institutional investor base, though some market observers note that such events can also represent late-cycle catalysts when much of the anticipated buying has already occurred. In other words, buy the rumour/news, sell the event.
4DMedical’s transformation from speculative medical technology developer to commercial-stage imaging services provider has been underpinned by a series of high-profile hospital partnerships and regulatory milestones. The company recently secured deployment of its CT:VQ lung ventilation imaging technology at the Mayo Clinic, one of the world’s most prestigious medical institutions, alongside agreements with Stanford University and expansion of lung-health screening programs across multiple hospitals in Brazil.
The company has also established multiple Cooperative Research and Development Agreements with U.S. Veterans Affairs centres, including facilities in West Los Angeles and Vanderbilt University Medical Center, focusing on functional lung imaging for conditions including burn-pit exposure and pulmonary fibrosis in veterans. These partnerships have been central to the investment thesis that 4DMedical’s technology is transitioning from experimental to standard-of-care status at leading institutions.
Regulatory progress has matched commercial momentum. The company recently obtained CE Mark approval for CT:VQ, opening the European market, and raised approximately A$80-85 million in new capital to fund the expansion. A separate A$150 million capital raise and A$22.6 million from option exercises in October 2025 have provided substantial financial resources, though the heavy reliance on equity financing has raised questions among some analysts about long-term capital intensity and dilution.
The company’s partnership with Philips yielded approximately US$10 million in CT:VQ orders, validating the OEM-channel strategy, while Olympus launched its SeleCT Screening emphysema program in the United States powered by 4DMedical’s lung-density analysis technology. These distribution partnerships offer ready-made channels to scale across large installed bases of imaging equipment.
Financial performance has shown strong revenue growth from a small base, with recent reports highlighting triple-digit percentage increases in quarterly revenues as hospital onboarding accelerates and scan volumes ramp. The company remains in investment mode, running operating losses while building out its commercial infrastructure across multiple geographies, though cash burn has been shrinking relative to revenue gains.
From a technical perspective, Tuesday’s price action exhibited classic characteristics of an exhausted momentum move: a gap higher that failed to hold, a long upper wick, and a close at session lows. Yet the stock found support near late-March levels, suggesting the pullback may represent healthy consolidation within an ongoing uptrend rather than a trend reversal. The coming weeks will be critical, with the 20 April index inclusion serving as a natural focal point for sentiment and positioning.
Bull Case:
- ASX 200 inclusion drives structural institutional demand starting 20 April
- Mayo Clinic and Stanford adoptions validate technology as emerging standard of care
- CE Mark plus Philips and Olympus channels enable rapid global scaling
- Strong balance sheet from recent raises funds multi-year expansion without financing risk
- Large under-diagnosed respiratory disease populations provide substantial long-term revenue runway
Bear Case:
- Valuation implies perfect execution with little margin for revenue or adoption delays
- ASX disclosure query raises governance concerns and promotional tone red flags
- Heavy equity dilution from multiple raises increases long-term shareholder dilution risk
- Operating losses continue while path to profitability remains multi-year aspiration
- Technical exhaustion after 2000% gain suggests blow-off top and deeper correction risk
